Food companies at McCormick Place expo spotlight innovations amid economic uncertainty
Plant-based protein, less sugar and healthier options were common trends at the Institute of Food Technologists expo at McCormick Place. Tariffs were also a concern at the annual food science and technology show organized by IFT, a nonprofit scientific organization based in the Loop. More than 1,000 exhibitors attended the four-day convention that ended Wednesday,including […]
Can Wegovy & Ozempic Drive Another Strong Quarter for Novo Nordisk?
Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II diabetes (T2D) and Wegovy for obesity. Ozempic and Wegovy include the same compound, semaglutide, a GLP-1 receptor agonist. Both medications have experienced rapid demand due to increased prescription rates following label expansions, which have driven up […]
Turning the Page for Obesity Therapies — Addressing Tolerability and Delivery
As scientists and researchers figure out the right balance of GLP-1 to glucagon ratio and a better drug delivery method, we are beginning to turn the page for the many individuals suffering from obesity. The post Turning the Page for Obesity Therapies — Addressing Tolerability and Delivery appeared first on MedCity News.
GLP-1 RAs Protective Against Stroke, Neurodegeneration?
GLP-1 RAs used by adults with type 2 diabetes and obesity is linked to lower risk for dementia, stroke, and mortality vs other antidiabetic drugs, a new study shows. Medscape Medical News
From Lab to Landmark Therapy: Meet the Woman Behind GLP-1
Biochemist Svetlana Mojsov, honored for GLP-1 research that has transformed metabolic disease care, says she’s grateful to have contributed to something that’s helped so many. Medscape
💪 GLP-1s: Diabetes, Weight Loss, and Cancer Reduction
This source explores the impact of semaglutide, a weight loss medication, on muscle mass, glucose regulation, and bone health in adults with obesity. It highlights that muscle loss is a common consequence of weight reduction, particularly with semaglutide, and this loss can negatively affect glucose homeostasis and bone mineral density. The study indicates that older […]
Can Ozempic and other GLP-1 drugs be substitute for work outs? Dr Ambrish Mithal and Raj Ganpath discuss
Endocrinologist Dr Ambrish Mithal, the author of the recently-released book, The Weight Loss Revolution, talks to fitness and nutrition coach, Raj Ganpath, co-founder of The Quad, to decode GLP-1 drugs. Should you take them?
An overview of randomized clinical trials of fixed‐ratio combinations of basal insulin plus GLP‐1RA (injectable therapy): Lessons for advancing therapy in people with type 2 diabetes
Abstract Advancing therapy in T2DM with injectables, i.e., basal insulin (BI) and GLP-1 receptor agonists (GLP-1RAs) is recommended after the failure of oral glucose lowering agents (OGLAs), BI alone, or BI in combination with OGLAs, especially in persons with, or at high risk of atherosclerotic cardiovascular disease (ASCVD). BI and GLP-1RAs can be administered separately […]
Neurobeachin (NBEA) is a novel gene associated with GLP‐1 receptor agonist associated weight loss
Abstract Aims Nearly 42% of adults in the United States have obesity, a significant risk factor for many cardiometabolic diseases and cancers. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are promising interventions for weight loss, but their efficacy varies significantly across individuals. This study investigates the role of neurobeachin (NBEA), a gene that encodes a protein kinase […]
GLP-1 weight-loss drugs are reshaping modern dating and intimacy
GLP-1 weight-loss drugs are changing how people date and connect. In a nationally representative survey of 2,000 single U.S. adults (ages 18 to 91) led by the Kinsey Institute at Indiana University with DatingNews.com, GLP-1 users reported a wide range of physical, social, and psychological shifts they attributed to the drug.